FR3122991A1 - PLANT EXTRACT WITH CRASSULACEAN ACID METABOLISM FOR USE IN THE TREATMENT OF DYSMENORRHEA AND/OR PAIN RELATED TO MENSTRUAL SPASMS AND CRAMPS - Google Patents
PLANT EXTRACT WITH CRASSULACEAN ACID METABOLISM FOR USE IN THE TREATMENT OF DYSMENORRHEA AND/OR PAIN RELATED TO MENSTRUAL SPASMS AND CRAMPS Download PDFInfo
- Publication number
- FR3122991A1 FR3122991A1 FR2105309A FR2105309A FR3122991A1 FR 3122991 A1 FR3122991 A1 FR 3122991A1 FR 2105309 A FR2105309 A FR 2105309A FR 2105309 A FR2105309 A FR 2105309A FR 3122991 A1 FR3122991 A1 FR 3122991A1
- Authority
- FR
- France
- Prior art keywords
- extract
- dysmenorrhea
- acid metabolism
- menstrual
- cramps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000007101 Muscle Cramp Diseases 0.000 title claims abstract description 16
- 206010013935 Dysmenorrhoea Diseases 0.000 title claims abstract description 15
- 208000005171 Dysmenorrhea Diseases 0.000 title claims abstract description 10
- 230000036407 pain Effects 0.000 title claims abstract description 10
- 208000002193 Pain Diseases 0.000 title claims abstract description 9
- 230000004060 metabolic process Effects 0.000 title claims abstract description 9
- 208000005392 Spasm Diseases 0.000 title claims abstract description 8
- 239000002253 acid Substances 0.000 title claims abstract description 8
- 238000011282 treatment Methods 0.000 title claims abstract description 7
- 230000002175 menstrual effect Effects 0.000 title claims abstract description 5
- 239000000419 plant extract Substances 0.000 title abstract description 6
- 239000000284 extract Substances 0.000 claims abstract description 12
- 241000196324 Embryophyta Species 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 3
- 235000004727 Opuntia ficus indica Nutrition 0.000 claims description 2
- 240000009297 Opuntia ficus-indica Species 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 1
- 239000000287 crude extract Substances 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 239000002798 polar solvent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 20
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 4
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 4
- 230000003821 menstrual periods Effects 0.000 description 4
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 230000029553 photosynthesis Effects 0.000 description 3
- 238000010672 photosynthesis Methods 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 201000009273 Endometriosis Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 108091000041 Phosphoenolpyruvate Carboxylase Proteins 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- YAHZABJORDUQGO-NQXXGFSBSA-N D-ribulose 1,5-bisphosphate Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)C(=O)COP(O)(O)=O YAHZABJORDUQGO-NQXXGFSBSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 1
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010046809 Uterine pain Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 239000003688 hormone derivative Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960004400 levonorgestrel Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical class 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Reproductive Health (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
EXTRAIT DE VEGETAL A METABOLISME ACIDE CRASSULACEEN pour utilisation dans le traitement de la dysménorrhée et/ou des douleurs liées aux spasmes et crampes menstruels La présente invention concerne un extrait d’au moins un végétal à métabolisme acide crassulacéen pour utilisation dans le traitement de la dysménorrhée. La présente invention concerne également une composition pharmaceutique comprenant un extrait selon l’invention.PLANT EXTRACT WITH CRASSULACEAN ACID METABOLISM for use in the treatment of dysmenorrhea and/or pain associated with menstrual spasms and cramps The present invention relates to an extract of at least one plant with crassulacean acid metabolism for use in the treatment of dysmenorrhea . The present invention also relates to a pharmaceutical composition comprising an extract according to the invention.
Description
La présente invention est relative au domaine des extraits de végétaux et leurs utilisations en tant que principes actifs purifiés dans des compositions alimentaires ou pharmaceutiques.The present invention relates to the field of plant extracts and their uses as purified active principles in food or pharmaceutical compositions.
ART ANTERIEURPRIOR ART
Les plantes succulentes ou malacophytes appelées également « plantes grasses » sont des plantes dont la photosynthèse utilise une voie spécifique appelée CAM (métabolisme acide crassulacéen) où le dioxyde de carbone se fixe sur une chaîne de sucres composé de trois atomes de carbone (plantes en C3) alors que la photosynthèse est habituellement réalisée avec des sucres contenant quatre atomes de carbone (plantes en C4). Cette photosynthèse utilise une succession de deux enzymes : le phosphoénolpyruvate carboxylase (PEPc) dans le cytosol, et la ribulose-1,5-bisphosphate carboxylase/oxygénasses (Rubisco) au niveau des chloroplastes. Les plantes de la famille des Crassulaceae et des Cactaceae par exemple utilisent ce métabolisme qui leur permet de survivre dans des milieux arides.Succulent plants or malacophytes also called "fat plants" are plants whose photosynthesis uses a specific pathway called CAM (crassulacean acid metabolism) where carbon dioxide attaches to a chain of sugars composed of three carbon atoms (plants in C3 ) while photosynthesis is usually carried out with sugars containing four carbon atoms (C4 plants). This photosynthesis uses a succession of two enzymes: phosphoenolpyruvate carboxylase (PEPc) in the cytosol, and ribulose-1,5-bisphosphate carboxylase/oxygenasses (Rubisco) in the chloroplasts. Plants of the Crassulaceae and Cactaceae families, for example, use this metabolism which allows them to survive in arid environments.
La guanosine monophosphate cyclique (GMPc) agit comme un second messager pour intervenir au niveau des différents tissus dans plusieurs processus biologiques d’une grande importance. Les bénéfices de la GMPc pour la santé sont dus essentiellement à ses effets positifs sur la croissance et la survie de nombreux types cellulaires comme les cardiomyocytes, les cellules hématopoïétiques et vasculaires, les érythrocytes, les plaquettes, les ostéoblastes et les cellules ciliées sensorielles. Les propriétés anti-inflammatoires et vasorelaxants de la GMPc peuvent conférer à ce nucléotide un rôle physiologique important. Il intervient dans la relaxation des fibres musculaires lisses caractérisant les muscles creux. Il est donc essentiel de maintenir la concentration de la GMPc à travers toutes les cellules de l’organisme à des niveaux suffisants pour assurer la décontraction des fibres musculaires du cœur, des vaisseaux, des voies aérodigestives, des organes sexuels, des voies pulmonaires etc. La GMPc est dégradée par la Phosphodiestérase de type 5 (PDE5) conduisant à la contraction de ces fibres musculaire lisses.Cyclic guanosine monophosphate (cGMP) acts as a second messenger to intervene at the level of different tissues in several biological processes of great importance. The health benefits of cGMP are mainly due to its positive effects on the growth and survival of many cell types such as cardiomyocytes, hematopoietic and vascular cells, erythrocytes, platelets, osteoblasts and sensory hair cells. The anti-inflammatory and vasorelaxant properties of cGMP may give this nucleotide an important physiological role. It intervenes in the relaxation of the smooth muscle fibers characterizing the hollow muscles. It is therefore essential to maintain the concentration of cGMP through all the cells of the body at sufficient levels to ensure the relaxation of the muscle fibers of the heart, the vessels, the aerodigestive tracts, the sexual organs, the pulmonary tracts, etc. cGMP is degraded by phosphodiesterase type 5 (PDE5) leading to contraction of these smooth muscle fibers.
L’utilisation d’extraits de plantes de différentes espèces comme activateurs de l’expression de la GMPc est abordé dans la littérature par exemple dans US2010119627 ou WO18134848. L’effet activateur de la GMPc de ces extraits est en majorité des cas lié à l’inhibition de sa dégradation par l’enzyme spécifique de son substrat la PDE5.The use of plant extracts from different species as cGMP expression activators is discussed in the literature, for example in US2010119627 or WO18134848. The cGMP activating effect of these extracts is in most cases linked to the inhibition of its degradation by the specific enzyme of its substrate, PDE5.
L’utilisation d’extraits de plantes CAM comme activateurs de la synthèse de GMPc ainsi que leur utilisation dans le traitement de la dysménorrhée n’a encore jamais été abordée dans la littérature.The use of CAM plant extracts as activators of cGMP synthesis as well as their use in the treatment of dysmenorrhea has never been addressed in the literature.
La dysménorrhée est le terme médical pour désigner les spasmes et crampes menstruels se traduisant par des douleurs. La plupart des femmes qui sont menstruées ont quelques crampes. Pour certaines femmes, la dysménorrhée peut être sérieuse et invalidante. Les spasmes et crampes au bas-ventre provoquent des douleurs qui s’étendent parfois jusqu’à la région lombaire, aux hanches et aux jambes. Les douleurs débutent un peu avant ou au commencement de la période menstruelle, et la plupart du temps, durent d’un à trois jours. Certaines femmes vont également avoir des nausées, des maux de tête, de la diarrhée ou être constipées.Dysmenorrhea is the medical term for menstrual spasms and cramps resulting in pain. Most women who are menstruating have some cramping. For some women, dysmenorrhea can be serious and debilitating. Spasms and cramps in the lower abdomen cause pain that sometimes extends to the lumbar region, hips and legs. The pains start a little before or at the beginning of the menstrual period, and most of the time, last from one to three days. Some women will also experience nausea, headaches, diarrhea, or constipation.
La dysménorrhée peut être primaire ou secondaire. La dysménorrhée primaire est une douleur qui n’est causée par aucun trouble gynécologique. Ce sont des types de spasmes ou crampes que subissent la plupart des femmes et qui sont plus ou moins tolérés. Les prostaglandines sont des facteurs autocrines ou paracrines de nature lipidiques différents des hormones en ce que la sécrétion est toujours proche du récepteur, qui sont libérées au cours de la période menstruelle. Leurs sécrétions seraient associées aux contractions utérines et aux douleurs. Il a également été mis en évidence que les femmes ayant une dysménorrhée plus grave ont aussi un taux plus élevé d’une hormone appelée vasopressine. Celle-ci rend les contractions utérines plus intenses et peut-être plus douloureuses. La dysménorrhée secondaire fait référence à une douleur causée par un trouble gynécologique sous-jacent, comme l’endométriose, un léiomyome utérin ou l’adénomyose utérine (une tumeur non cancéreuse ayant les caractéristiques de l’endométriose, située dans la paroi musculaire de l’utérus).Dysmenorrhea can be primary or secondary. Primary dysmenorrhea is pain that is not caused by any gynecological disorder. These are types of spasms or cramps that most women experience and are more or less tolerated. Prostaglandins are autocrine or paracrine factors of a lipid nature different from hormones in that the secretion is always close to the receptor, which are released during the menstrual period. Their secretions would be associated with uterine contractions and pain. It has also been shown that women with more severe dysmenorrhea also have higher levels of a hormone called vasopressin. This makes uterine contractions more intense and possibly more painful. Secondary dysmenorrhea refers to pain caused by an underlying gynecological disorder, such as endometriosis, uterine leiomyoma, or uterine adenomyosis (a non-cancerous tumor with characteristics of endometriosis, located in the muscle wall of the 'uterus).
La dysménorrhée primaire est souvent traitée par des médicaments anti-inflammatoires comme le paracétamol ou acétaminophène, l’ibuprofène, le naproxen, l’acide méfénamique etc. Elle peut également être traitée avec des contraceptifs oraux, cela rend la période menstruelle moins fatigante, plus régulière, et diminue la libération des prostaglandines. Également avec le dispositif intra-utérin au lévonorgestrel, il libère une petite quantité de progestérone et rend les périodes menstruelles moins fatigantes et diminue la production de prostaglandines. Les hormones synthétiques peuvent également être utilisées pour supprimer le cycle menstruel comme le danazol (Danocrine) ou encore l’acétate de leuprolide (Lupron) qui sont cependant des médicaments très chers et ont éventuellement des effets secondaires graves.Primary dysmenorrhea is often treated with anti-inflammatory drugs such as paracetamol or acetaminophen, ibuprofen, naproxen, mefenamic acid etc. It can also be treated with oral contraceptives, this makes the menstrual period less tiring, more regular, and decreases the release of prostaglandins. Also with the levonorgestrel intrauterine device, it releases a small amount of progesterone and makes menstrual periods less tiring and decreases the production of prostaglandins. Synthetic hormones can also be used to suppress the menstrual cycle such as danazol (Danocrine) or leuprolide acetate (Lupron) which are however very expensive drugs and possibly have serious side effects.
Les traitements de la dysménorrhée primaire sont donc essentiellement anti inflammatoires ou suppresseurs de cycle menstruel.Treatments for primary dysmenorrhea are therefore essentially anti-inflammatory or menstrual cycle suppressors.
La demanderesse a mis en évidence de manière surprenante que dans le cas de la dysménorrhée primaire, les crampes sont provoquées par une hausse de la contractilité de l'utérus et des spasmes artériolaires induits par les prostaglandines. La contractibilité du muscle utérin comme celui de la tunique artérielle est semblable à celle de tous les muscles lisses. La GMPc est l’un des points clefs de la relaxation de la cellule musculaire lisse. L’excès de contractions de la cellule du muscle lisse, quelle qu’en soit l’origine a toujours comme corolaire une dégradation de la GMPc. Toutes les études suggèrent que le GMPc est plus efficace pour faire baisser le calcium intracellulaire que l’AMPc dans les cellules du muscle lisse. La GMPc est produite par action d’une guanylate cyclase (GC) soluble, elle va être dégradée par des phosphodiestérases et plus particulièrement par la PDE5.The applicant has demonstrated, surprisingly, that in the case of primary dysmenorrhea, the cramps are caused by an increase in the contractility of the uterus and arteriolar spasms induced by prostaglandins. The contractibility of the uterine muscle, like that of the arterial tunica, is similar to that of all the smooth muscles. cGMP is one of the key points of smooth muscle cell relaxation. Excess contraction of the smooth muscle cell, whatever its origin, always has as a corollary a degradation of cGMP. All studies suggest that cGMP is more effective in lowering intracellular calcium than cAMP in smooth muscle cells. cGMP is produced by the action of a soluble guanylate cyclase (GC), it will be degraded by phosphodiesterases and more particularly by PDE5.
La demanderesse a démontré de façon surprenante qu’un extrait de végétal à métabolisme acide crassulacéen tel qu’Opuntia ficus- indicapossède une activité sur l’expression de la GMPc et est efficace dans le traitement de la dysménorrhée notamment. L’observation clinique montre une réduction considérable des douleurs liées aux spasmes et crampes menstruels.The applicant has demonstrated surprisingly that a plant extract with crassulacean acid metabolism such as Opuntia ficus- indica has an activity on the expression of cGMP and is effective in the treatment of dysmenorrhea in particular. Clinical observation shows a considerable reduction in pain associated with menstrual spasms and cramps.
DESCRIPTION DES FIGURESDESCRIPTION OF FIGURES
La
La
La
La
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2105309A FR3122991B1 (en) | 2021-05-20 | 2021-05-20 | CRASSULACEAN ACID METABOLISM PLANT EXTRACT FOR USE IN THE TREATMENT OF DYSMENORRHEA AND/OR PAIN RELATED TO MENSTRUAL SPASMS AND CRAMPS |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR2105309A FR3122991B1 (en) | 2021-05-20 | 2021-05-20 | CRASSULACEAN ACID METABOLISM PLANT EXTRACT FOR USE IN THE TREATMENT OF DYSMENORRHEA AND/OR PAIN RELATED TO MENSTRUAL SPASMS AND CRAMPS |
| FR2105309 | 2021-05-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR3122991A1 true FR3122991A1 (en) | 2022-11-25 |
| FR3122991B1 FR3122991B1 (en) | 2024-05-31 |
Family
ID=78332825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR2105309A Active FR3122991B1 (en) | 2021-05-20 | 2021-05-20 | CRASSULACEAN ACID METABOLISM PLANT EXTRACT FOR USE IN THE TREATMENT OF DYSMENORRHEA AND/OR PAIN RELATED TO MENSTRUAL SPASMS AND CRAMPS |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR3122991B1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998029128A1 (en) | 1996-12-27 | 1998-07-09 | Inovat Sarl | Biologically active substances, method for obtaining and compositions containing them |
| WO2002005830A2 (en) * | 2000-07-14 | 2002-01-24 | Shantaram Govind Kane | Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof |
| US20100119627A1 (en) | 2006-12-11 | 2010-05-13 | Bjorn Feistel | SPECIAL EXTRACT AND USE THEREOF FOR INHIBITING THE DEGRADATION OF CYCLIC GUANOSINE MONOPHOSPHATE (cGMP) |
| KR20170122501A (en) * | 2016-04-27 | 2017-11-06 | 충북대학교 산학협력단 | Composition for preventing and treating dysmenorrhea and premature labor comprising non-polar solvent subfraction from Zingiber officinale extract |
| WO2018134848A1 (en) | 2017-01-20 | 2018-07-26 | Laila Nutraceuticals | Dietary supplements for inhibiting pde5 and increasing cgmp levels |
-
2021
- 2021-05-20 FR FR2105309A patent/FR3122991B1/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998029128A1 (en) | 1996-12-27 | 1998-07-09 | Inovat Sarl | Biologically active substances, method for obtaining and compositions containing them |
| WO2002005830A2 (en) * | 2000-07-14 | 2002-01-24 | Shantaram Govind Kane | Extracts from crassulacean acid metabolism (cam) mechanism plants and uses thereof |
| US20100119627A1 (en) | 2006-12-11 | 2010-05-13 | Bjorn Feistel | SPECIAL EXTRACT AND USE THEREOF FOR INHIBITING THE DEGRADATION OF CYCLIC GUANOSINE MONOPHOSPHATE (cGMP) |
| KR20170122501A (en) * | 2016-04-27 | 2017-11-06 | 충북대학교 산학협력단 | Composition for preventing and treating dysmenorrhea and premature labor comprising non-polar solvent subfraction from Zingiber officinale extract |
| WO2018134848A1 (en) | 2017-01-20 | 2018-07-26 | Laila Nutraceuticals | Dietary supplements for inhibiting pde5 and increasing cgmp levels |
Non-Patent Citations (3)
| Title |
|---|
| BALDASSANO S. ET AL: "Inhibition of the Mechanical Activity of Mouse Ileum by Cactus Pear ( Opuntia Ficus Indica , L, Mill.) Fruit Extract and Its Pigment Indicaxanthin", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 58, no. 13, 2 June 2010 (2010-06-02), US, pages 7565 - 7571, XP055888291, ISSN: 0021-8561, DOI: 10.1021/jf100434e * |
| BALDASSANO SARA ET AL: "Inhibitory effects of indicaxanthin on mouse ileal contractility: Analysis of the mechanism of action", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 658, no. 2-3, 1 May 2011 (2011-05-01), NL, pages 200 - 205, XP055888263, ISSN: 0014-2999, DOI: 10.1016/j.ejphar.2011.02.034 * |
| DATABASE WPI Week 201782, Derwent World Patents Index; AN 2017-791173, XP002805662 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR3122991B1 (en) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Breton et al. | GTH I and GTH II secretion profiles during the reproductive cycle in female rainbow trout: relationship with pituitary responsiveness to GnRH-A stimulation | |
| FR2914188A1 (en) | Pharmaceutical composition, useful as medicine, preferably as drugs in the treatment of degenerative diseases, comprises oxime based chloestenone compounds or their esters or derivatives, and oil or its mixture | |
| FR2813084A1 (en) | Lactic acid bacteria formulation for improving bowel movement, e.g. for treating diarrhea, comprising live microbes of Lactobacillus clearans and Enterococcus faecalis | |
| KR930006432B1 (en) | Pharmaceutical compositions for treating acne | |
| FR3122991A1 (en) | PLANT EXTRACT WITH CRASSULACEAN ACID METABOLISM FOR USE IN THE TREATMENT OF DYSMENORRHEA AND/OR PAIN RELATED TO MENSTRUAL SPASMS AND CRAMPS | |
| KR20180137605A (en) | Use of a combination of d-aspartic and l-aspartic acids or salts thereof for the treatment of male infertility | |
| WO2007014379A2 (en) | A lipidic extract from lepidium meynii and its effect on the libido | |
| WO2003074011A1 (en) | Cosmetic use of phytosphingosine as slimming agent and cosmetic compositions comprising phytosphingosine | |
| FR2711529A1 (en) | Composition based on amino acids intended for the treatment of an infection or an aggression causing an inflammatory reaction, in animals and in humans. | |
| WO2019092274A1 (en) | Pentacyclic triterpenes for the treatment of an oral disease | |
| EA013948B1 (en) | Preparation stimulating sexual function | |
| BE1026496B1 (en) | Compound and composition for use in the treatment of premenstrual syndrome and / or premenstrual dysphoric disorder | |
| EP1194136A1 (en) | Non-solid composition for local application | |
| KR102035281B1 (en) | Composition with the ethyl acetate extract of Fomes fomentarius for the relaxation of blood vessel | |
| FR2591890A1 (en) | THERAPEUTIC USE COMPOSITION COMPRISING ORGANO-SILICY COMPOUNDS | |
| FR2619313A1 (en) | NOVEL COMPOSITIONS OF MINERAL ELEMENTS AND / OR OLIGOELEMENTS AND PROCESS FOR THEIR PREPARATION | |
| BE1024391B1 (en) | Composition for use in the preventive and / or curative treatment of non-alcoholic fatty liver disease | |
| EP1978827A1 (en) | Food supplement based on group b vitamins, trace elements and w-3 and/or w-6 fatty acids and use of this food supplement in the simultaneous treatment of localized cellulite and slackening of the skin | |
| BE1026393B1 (en) | Composition for use in the treatment of osteopenia and / or osteoporosis | |
| BE1026580B1 (en) | Composition for use in the preventive and / or curative treatment of non-alcoholic fatty liver disease | |
| FR3087337A1 (en) | DERMATOLOGICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF MASTODYNIA | |
| EL-GOHARY et al. | Use of the male chemosterilant: α-chlorohydrin in the control of house rats, Rattus rattus | |
| Elhajili et al. | Effet diurétique de l'infusion de fleurs de lavandula officinalis | |
| EP2332556A1 (en) | Use of yeasts for treating stomach or intestinal ulcers induced by gastrotoxic agents | |
| RU2014840C1 (en) | Agent showing wound-healing and hepatoprotective effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 2 |
|
| PLSC | Publication of the preliminary search report |
Effective date: 20221125 |
|
| PLFP | Fee payment |
Year of fee payment: 3 |
|
| PLFP | Fee payment |
Year of fee payment: 4 |